Protalix BioTherapeutics, Inc. (PLX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Protalix BioTherapeutics, Inc. Do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. (PLX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Dror Bashan and employs approximately 200 people, headquartered in CARMIEL, New Jersey. With a market capitalization of $176M, PLX is one of the notable companies in the Healthcare sector.
Protalix BioTherapeutics, Inc. (PLX) Stock Rating — Reduce (April 2026)
As of April 2026, Protalix BioTherapeutics, Inc. receives a Reduce rating with a composite score of 34.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PLX ranks #3,143 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Protalix BioTherapeutics, Inc. ranks #468 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
PLX Stock Price and 52-Week Range
Protalix BioTherapeutics, Inc. (PLX) currently trades at $2.30. The stock gained $0.02 (0.9%) in the most recent trading session. The 52-week high for PLX is $3.19, which means the stock is currently trading -27.9% from its annual peak. The 52-week low is $1.32, putting the stock 74.2% above its annual trough. Recent trading volume was 394K shares, suggesting relatively thin trading activity.
Is PLX Overvalued or Undervalued? — Valuation Analysis
Protalix BioTherapeutics, Inc. (PLX) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 82.61x, compared to the Healthcare sector average of 23.63x — a premium of 250%. The price-to-book ratio stands at 3.66x, versus the sector average of 2.75x. The price-to-sales ratio is 2.87x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PLX trades at 58.86x EV/EBITDA, versus 6.34x for the sector.
At current multiples, Protalix BioTherapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Protalix BioTherapeutics, Inc. Profitability — ROE, Margins, and Quality Score
Protalix BioTherapeutics, Inc. (PLX) earns a quality factor score of 33/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 4.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 2.6% versus the sector average of -33.1%.
On a margin basis, Protalix BioTherapeutics, Inc. reports gross margins of 47.1%, compared to 71.5% for the sector. The operating margin is 0.2% (sector: -66.1%). Net profit margin stands at -0.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 32.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
PLX Debt, Balance Sheet, and Financial Health
Protalix BioTherapeutics, Inc. has a debt-to-equity ratio of 71.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.51x, indicating strong short-term liquidity. Total debt on the balance sheet is $7M. Cash and equivalents stand at $14M.
PLX has a beta of 0.89, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Protalix BioTherapeutics, Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Protalix BioTherapeutics, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Protalix BioTherapeutics, Inc. reported revenue of $62M and earnings per share (EPS) of $-0.08. Net income for the quarter was $2M. Gross margin was 47.1%. Operating income came in at $3M.
In FY 2025, Protalix BioTherapeutics, Inc. reported revenue of $53M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-7M. Gross margin was 48.8%. Revenue grew -1.2% year-over-year compared to FY 2024. Operating income came in at $-6M.
In Q3 2025, Protalix BioTherapeutics, Inc. reported revenue of $18M and earnings per share (EPS) of $0.03. Net income for the quarter was $2M. Gross margin was 53.4%. Revenue grew -0.6% year-over-year compared to Q3 2024. Operating income came in at $2M.
In Q2 2025, Protalix BioTherapeutics, Inc. reported revenue of $16M and earnings per share (EPS) of $0.00. Net income for the quarter was $164,000. Gross margin was 62.5%. Revenue grew 16.2% year-over-year compared to Q2 2024. Operating income came in at $1M.
Over the past 8 quarters, Protalix BioTherapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $13M to $62M. Investors analyzing PLX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
PLX Dividend Yield and Income Analysis
Protalix BioTherapeutics, Inc. (PLX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
PLX Momentum and Technical Analysis Profile
Protalix BioTherapeutics, Inc. (PLX) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 23/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
PLX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Protalix BioTherapeutics, Inc. (PLX) ranks #468 out of 838 stocks based on the Blank Capital composite score. This places PLX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing PLX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PLX vs S&P 500 (SPY) comparison to assess how Protalix BioTherapeutics, Inc. stacks up against the broader market across all factor dimensions.
PLX Next Earnings Date
No upcoming earnings date has been announced for Protalix BioTherapeutics, Inc. (PLX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy PLX? — Investment Thesis Summary
The quantitative profile for Protalix BioTherapeutics, Inc. suggests caution. The quality score of 33/100 flags below-average profitability. The value score of 30/100 indicates premium valuation. High volatility (stability score 32/100) increases portfolio risk.
In summary, Protalix BioTherapeutics, Inc. (PLX) earns a Reduce rating with a composite score of 34.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PLX stock.
Related Resources for PLX Investors
Explore more research and tools: PLX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PLX head-to-head with peers: PLX vs AZN, PLX vs SLGL, PLX vs VMD.